Evaluation of the Effectiveness of Dantrolene Sodium against Digoxininduced Cardiotoxicity in Adult Rats

Mahmoud Zardast1, Kosar Behmanesh2, Tahereh Farkhondeh3

  • 1Department of Pathology, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.

Abstract

Insights

Dantrolene at 10 mg/kg demonstrated cardioprotective effects against digoxin-induced cardiotoxicity in rats. This suggests dantrolene may mitigate heart damage and hyperkalemia associated with digoxin poisoning.

Area of Science:

  • Pharmacology
  • Cardiovascular Toxicology
  • Experimental Medicine

Background:

  • Digoxin poisoning is a clinical concern in patients receiving digoxin.
  • Dantrolene is being investigated as a potential therapeutic agent for digoxin-induced cardiotoxicity.

Purpose of the Study:

  • To assess the protective efficacy of dantrolene against digoxin-induced cardiotoxicity in a male rat model.

Main Methods:

  • Wistar rats were divided into seven groups, receiving normal saline, ethanol, dantrolene, digoxin, or combinations thereof.
  • Serum electrolytes (K, Na, Ca, Mg) and creatine phosphokinase (CPK) were measured.
  • Cardiac tissue underwent histopathological evaluation for signs of damage and inflammation.

Main Results:

  • Digoxin administration led to cardiac tissue degeneration and increased potassium levels.
  • Dantrolene at 10 mg/kg significantly improved cardiac histology and normalized calcium levels.
  • A high dose of dantrolene (20 mg/kg) was associated with increased potassium levels.

Conclusions:

  • Dantrolene (10 mg/kg) exhibits cardioprotective properties in a rat model of digoxin toxicity.
  • The cardioprotective mechanism may involve mitigating cardiac remodeling and hyperkalemia.
  • Further studies are required to establish optimal therapeutic and toxic doses of dantrolene.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
664
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
722
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
16
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
930